VIVS

VivoSim Labs Inc

0.1545

Nov 02 • 8:09 AM ET -0.0001 (-0.06%)

Healthcare Biotechnology USA Nano NASD

Peers: CSBR ABSI CRL LTRN CERT ISPC HBIO MEDP LAB QTRX

Index	-
Market Cap	2.56M
Enterprise Value	1.21M
Income	-12.34M
Sales	0.11M
Book/sh	-0.73
Cash/sh	0.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	15
IPO	Feb 14, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	23.26
P/B	-
P/C	1.53
P/FCF	-
EV/EBITDA	-
EV/Sales	10.98
Quick Ratio	1.70
Current Ratio	1.70
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-4.47
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	39.18% 28.81%
Sales past 3/5Y	-29.26% -
EPS Y/Y TTM	-194.95%
Sales Y/Y TTM	-21.13%
EPS Q/Q	77.51%
Sales Q/Q	-51.35%
Earnings	-
EPS/Sales Surpr.	46.15% -26.83%

Insider Own	16.62%
Insider Trans	0.36%
Inst Own	11.15%
Inst Trans	0.46%
ROA	-155.93%
ROE	-343.10%
ROIC	-
Gross Margin	-73.21%
Oper. Margin	-10116.96%
Profit Margin	-11016.07%
SMA20	-6.82%
SMA50	-29.93%
SMA200	-85.48%
Trades

Shs Outstand	16.59M
Shs Float	13.83M
Short Float	4.33%
Short Ratio	0.22
Short Interest	0.60M
52W High	3.40 -95.46%
52W Low	0.14 9.03%
Volatility	9.90% 10.42%
ATR (14)	0.02
RSI (14)	36.02
Beta	1.58
Rel Volume	0.37
Avg Volume	2.75M
Volume	51,334

Perf Week	1.64%
Perf Month	-21.33%
Perf Quarter	-57.90%
Perf Half Y	-89.04%
Perf YTD	-91.46%
Perf Year	-94.28%
Perf 3Y	-99.06%
Perf 5Y	-99.79%
Perf 10Y	-99.98%
Recom	3.00
Target Price	64.80
Prev Close	0.15
Price	0.15
Change %	-0.06%

Consensus

Hold

Avg. Price Target

$64.80

Implied Upside

+41,841.7%

Analysts5incl. previous ratings

Rating Distribution3 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Dec 13, 2018	Initiated	HH.C. Wainwright	Buy	$2.50	+1,518.1%
Nov 10, 2017	Downgrade	RRaymond James	Outperform → Mkt Perform
Jan 25, 2017	Initiated	RRaymond James	Outperform
Aug 11, 2015	Downgrade	CCantor Fitzgerald	Buy → Hold
Jun 29, 2015	Initiated	PPiper Jaffray	Overweight	$5	+3,136.2%
Jun 29, 2015	Initiated	JJefferies	Buy	$5	+3,136.2%

Oct-21-26 08:05AM	VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling (GlobeNewswire)
Oct-07-26 08:05AM	VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods (GlobeNewswire) -5.15%
Sep-16-26 08:05AM	VivoSim Labs Unveils New NAMkind Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs (GlobeNewswire)
Sep-01-26 08:05AM	VivoSim Labs to Add Rat Liver Model to NAMkind Platform (GlobeNewswire)
Aug-12-26 05:52PM	VivoSim: Fiscal Q1 Earnings Snapshot (Associated Press) -5.81%
08:05AM	Loading…
Aug-06-26 08:05AM	VivoSim Provides Financial and Listing Compliance Update (GlobeNewswire) -9.24%
Jul-21-26 10:28AM	VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS) (InvestorsHub) -10.87%
08:05AM	VivoSim Enters China with First Commercial Sales of NAMkind Toxicology Screening and Efficacy Testing Services (GlobeNewswire)
Jul-16-26 08:30AM	VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor (GlobeNewswire) -28.06%
Jul-15-26 10:46AM	VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth (InvestorsHub)
08:05AM	VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 (GlobeNewswire)
Jul-14-26 05:12PM	VivoSim: Fiscal Q4 Earnings Snapshot (Associated Press)
Jun-29-26 08:05AM	VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting (GlobeNewswire)
Apr-28-26 08:05AM	VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results - Without Animal Testing (GlobeNewswire)
Apr-01-26 08:05AM	VivoSim Announces Pricing of up to a $4 Million Public Offering (GlobeNewswire) +13.29%
08:05AM	Loading…
Mar-24-26 08:05AM	VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs (GlobeNewswire)
Mar-03-26 08:05AM	VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales (GlobeNewswire) -12.73%
Feb-11-26 08:05AM	VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego (GlobeNewswire)
Feb-02-26 06:59AM	NIO January Deliveries Nearly Double Year On Year (GuruFocus.com) -16.78%
Jan-29-26 04:05PM	VivoSim Expands Asia-Pacific Access to NAMKind Human-Based Toxicology Services Through New Distributor Agreement in Korea and China (GlobeNewswire) +71.76%
Jan-06-26 08:05AM	VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer (GlobeNewswire)
Jan-02-26 07:03AM	NIO Posts Record December and Q4 Deliveries as 2025 Volumes Surge (GuruFocus.com)
Dec-01-25 10:52AM	Nio Stock Slumps After Surprise November Delivery Drop (GuruFocus.com)
06:25AM	NIO Just Posted a 76% Delivery Surge--Here's What Investors Might Be Missing (GuruFocus.com)
Nov-04-25 07:51AM	NIO Stock Pops as EV Maker Smashes Delivery Record With 92% Surge (GuruFocus.com) -6.78%
Oct-01-25 05:45AM	NIO Stock Soars Past 52-Week High After Record Deliveries (Benzinga) +9.93%
Sep-02-25 05:40AM	NIO, XPeng, Li Auto Log Strong August Deliveries Highlighting China's EV Momentum (Benzinga)
Aug-14-25 08:05AM	VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer (GlobeNewswire)
Aug-12-25 04:44PM	VivoSim: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +6.05%
May-13-25 08:05AM	VivoSim's NAMKind Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference (GlobeNewswire)
08:05AM	Loading…
May-07-25 08:05AM	VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference (GlobeNewswire)
Apr-24-25 08:05AM	VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market (GlobeNewswire) -8.33%
Apr-23-25 08:05AM	VivoSim to Carry Forward Organovo 3D Bioprinting (GlobeNewswire)
Apr-02-25 08:05AM	Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements (GlobeNewswire)
Mar-27-25 08:05AM	Organovo Provides Business Update (GlobeNewswire) -13.50%
Mar-25-25 11:25AM	Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company (GlobeNewswire) -5.02%
Mar-19-25 08:05AM	Organovo Announces Reverse Stock Split (GlobeNewswire) -32.61%
Mar-11-25 07:00AM	Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-06-25 08:05AM	Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises (GlobeNewswire)
Feb-25-25 08:05AM	Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company (GlobeNewswire) +244.17%
Feb-19-25 09:17AM	Organovo: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Jan-06-25 08:05AM	Organovo Announces Appointment of Norman Staskey as Chief Financial Officer (GlobeNewswire) +7.15%
Nov-20-24 08:05AM	Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting (GlobeNewswire)
Nov-13-24 08:06AM	Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases (GlobeNewswire)
Nov-08-24 04:15PM	Organovo: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -6.60%
Jul-16-24 08:05AM	Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis (GlobeNewswire) -8.55%
Jun-03-24 11:52AM	ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace) +5.78%
May-21-24 08:05AM	Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease (GlobeNewswire)
May-14-24 11:00AM	Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) (GlobeNewswire)
May-09-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-08-24 08:00PM	Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering (GlobeNewswire) +5.49%
Apr-15-24 08:13AM	Organovo's fatty liver disease drug meets main goal in mid-stage study (Reuters) +33.65%
08:05AM	Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo (GlobeNewswire)
Mar-28-24 08:32PM	Top 15 3D Printing Companies in the US (Insider Monkey)
Feb-08-24 05:52PM	Organovo: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -10.00%
Jan-25-24 08:05AM	Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress (GlobeNewswire)
Jan-09-24 08:05AM	Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress (GlobeNewswire)
Dec-06-23 08:05AM	Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results (GlobeNewswire) -6.04%
Nov-13-23 08:05AM	CORRECTION Organovo Highlights FXR314 Combination Therapy Potential and Plan (GlobeNewswire) +5.93%
Nov-10-23 05:08AM	Organovo: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -7.53%
Nov-08-23 08:05AM	Organovo Highlights FXR314 Combination Therapy Potential and Plan (GlobeNewswire) -5.18%
Oct-10-23 07:18AM	ONVO: A Company With Great Technology to Impact Health Care (Zacks)
Sep-08-23 12:46PM	Organovo to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-25-23 07:36PM	Is Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com) -13.16%
Aug-23-23 08:05AM	Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data (GlobeNewswire) +5.43%
Jul-12-23 03:01AM	Net Asset Value(s) (Business Wire)
May-25-23 10:49AM	Cathie Wood is Selling These 12 Stocks in 2023 (Insider Monkey)
Mar-21-23 08:05AM	Organovo Announces FXR Program (GlobeNewswire)
Feb-10-23 05:12AM	Will Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely? (Simply Wall St.) -17.86%
Nov-15-22 08:05AM	Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohns Disease Drug Candidates (GlobeNewswire)
Sep-06-22 08:20AM	Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +13.42%
08:05AM	Organovo Announces Postponement of Annual Meeting of Stockholders (GlobeNewswire)
Jul-08-22 08:05AM	We're Not Very Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Rate (Simply Wall St.) +29.17%
May-17-22 08:05AM	Organovo Achieves 3D Tissue Model for Crohns Disease (GlobeNewswire) +5.86%
Mar-03-22 10:13PM	Why Organovo Holdings, Inc. Stock Soared 49.7% This Week (Motley Fool) -11.34%
Mar-01-22 08:05AM	UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents (GlobeNewswire) +5.90%
Feb-23-22 08:05AM	Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents (GlobeNewswire) +5.47%
Feb-18-22 04:00PM	Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:00PM	Organovo Welcomes New Sr. Vice President of Strategy and Business Development (GlobeNewswire)
Feb-12-22 02:09PM	10 3D Printing Companies to Watch in 2022 (Insider Monkey)
Feb-04-22 10:11AM	Cathie Wood Targets Illiquid Assets and Limits Exits in New Fund (Bloomberg)
Feb-02-22 12:00PM	Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents (GlobeNewswire)
Jan-21-22 11:37AM	15 Worst Stock Picks of Cathie Wood (Insider Monkey)
Jan-10-22 12:00PM	Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk (GlobeNewswire)
Dec-30-21 09:24AM	Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation (Simply Wall St.)
Nov-30-21 08:05AM	Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022 (GlobeNewswire)
Sep-17-21 04:10PM	Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum (GlobeNewswire) -7.57%
Jun-22-21 10:17AM	/C O R R E C T I O N from Source -- RBC Global Asset Management Inc./ (PR Newswire) +5.02%
Jun-15-21 11:38AM	Is Organovo Holdings Inc (ONVO) A Good Stock To Buy? (Insider Monkey)
Mar-02-21 08:05AM	Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE) (GlobeNewswire)
Feb-07-21 09:19AM	15 Biggest 3D Companies in the World (Insider Monkey)
Sep-03-20 04:05PM	Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -5.75% -11.54%
Aug-17-20 08:05AM	Organovo Announces One-for-Twenty Reverse Stock Split (GlobeNewswire) -13.52%
Jun-10-20 03:43PM	Hedge Fund Sentiment Is Stagnant On Organovo Holdings Inc (ONVO) (Insider Monkey) -7.54%
Apr-08-20 10:32AM	Edited Transcript of ONVO earnings conference call or presentation 9-Nov-17 10:00pm GMT (Thomson Reuters StreetEvents) +13.63%
07:53AM	The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO (Benzinga)
Apr-07-20 04:12PM	Organovo Announces Termination of Merger Agreement with Tarveda Therapeutics (Business Wire)
Apr-02-20 08:00AM	Organovo Holdings Founder Calls on Board of Directors to Accept Stockholders Opposition to the Illogical Merger With Tarveda Therapeutics (GlobeNewswire) -13.19%
Mar-31-20 06:30PM	Organovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of Stockholders (Business Wire) +43.36% -28.07%
03:25PM	Viscient Biosciences Will Bioprint 3D Lung Tissue to Aid Pandemic Research, and Viscient Founder Calls for Pause in Organovo Merger Attempt (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lialin Tony Serge	Chief Commercial Officer	Aug 31 '26	Buy	0.28	10,000	2,804	10,000	Sep 01 04:01 PM

VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.

Executive Chairman & Corporate SecretaryMr. Keith E. Murphy

PresidentMr. Norman Staskey

Ph.D.Dr. Amar A. Sethi M.D.

Chief Commercial OfficerMr. Tony Lialin

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VIVS

VivoSim Labs Inc

Upgrade your Finviz experience